Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
NCT04224415
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
C225+CPT-11
Sponsor
Yuhong Li